Syncom Formulations India Ltd-$
Syncom Formulations Q2 FY27 Standalone Net Profit at Rs. 2,539.55 Lakhs
RESULTS
▲ Positive Development
MEDIUM RISK
📅 Filed on BSE: 13 Nov 2026, 04:46 PM IST · BSE ID: e4e22674-e416-4445-85b2-9b53d1fdcd80
View Original BSE Filing (PDF)
💡
In Simple Terms
Syncom Formulations announced its quarterly financial results, showing revenues of Rs. 13,665.72 Lakhs and a net profit of Rs. 2,539.55 Lakhs.
🤖 AI Summary
- Standalone Revenue from Operations for Q2 FY27 reached Rs. 13,665.72 Lakhs.
- Net Profit for the quarter ended September 30, 2026, was Rs. 2,539.55 Lakhs.
- Basic Earnings Per Share (EPS) from continuing operations stood at Rs. 0.27 for Q2 FY27.
- Total comprehensive income for Q2 FY27 was Rs. 2,492.60 Lakhs.
- Total assets as of September 30, 2026, reported as Rs. 56,588.27 Lakhs.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Revenue from Operations (Q2 FY27)
13665.72 Lakhs
12.54
Net Profit (Q2 FY27)
2539.55 Lakhs
50.79
Total Income (Q2 FY27)
14270.14 Lakhs
12.66
Basic EPS (Q2 FY27)
0.27
50.00
Revenue from Operations (Half Year FY27)
26131.67 Lakhs
9.81
Net Profit (Half Year FY27)
4998.47 Lakhs
53.45
🏢 How This Affects the Company
The company's primary business segment, Pharmaceuticals Drugs & Formulations, contributed Rs. 14,127.28 Lakhs to segment revenue for Q2 FY27, indicating continued activity in its core market.
Syncom Formulations recorded a Q2 FY27 Standalone Net Profit of Rs. 2,539.55 Lakhs and Total Income of Rs. 14,270.14 Lakhs. Total assets increased to Rs. 56,588.27 Lakhs as of September 30, 2026, from Rs. 52,926.06 Lakhs on March 31, 2026.
👥 What This Means For Shareholders
✅
Action Required
No specific action is required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, specifically by the Q2 FY27 Basic EPS of Rs. 0.27.
🔍
Management Signal
The approval of the un-audited financial results by the Board of Directors signals management's continued oversight of financial reporting and performance.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List - track these upcoming events
Q3 FY27 results — monitor continuation of revenue and profit growth.
Segmental revenue breakdown — observe growth in Pharmaceuticals Drugs & Formulations.
Balance sheet analysis — track changes in current borrowings and cash reserves.
MEDIUM RISK
Increased current borrowings and decreased cash equivalents noted on the balance sheet.
💡 Investor Takeaway
Syncom Formulations reported Q2 FY27 Standalone Net Profit of Rs. 2,539.55 Lakhs, a substantial increase from Rs. 1,684.11 Lakhs in Q2 FY26. Revenue from Operations grew to Rs. 13,665.72 Lakhs from Rs. 12,143.51 Lakhs in the comparable prior period, demonstrating financial improvement.
⚖️ Strengths & Concerns
✅ Positives
- Q2 FY27 Standalone Net Profit from continuing operations was Rs. 2,539.55 Lakhs, an increase from Rs. 1,684.11 Lakhs in Q2 FY26.
- Revenue from Operations for Q2 FY27 increased to Rs. 13,665.72 Lakhs from Rs. 12,143.51 Lakhs in Q2 FY26.
⚠️ Concerns
- Current borrowings increased to Rs. 1,552.36 Lakhs as of September 30, 2026, from Rs. 68.13 Lakhs as of March 31, 2026.
- Cash And Cash Equivalents decreased to Rs. 29.76 Lakhs as of September 30, 2026, from Rs. 512.03 Lakhs as of March 31, 2026.
❓ Frequently Asked Questions
What was Syncom Formulations' Standalone Revenue from Operations in Q2 FY27?
Syncom Formulations reported a Standalone Revenue from Operations of Rs. 13,665.72 Lakhs for the quarter ended September 30, 2026 (Q2 FY27).
What was Syncom Formulations' Standalone Net Profit for Q2 FY27?
The Standalone Net Profit for Syncom Formulations for Q2 FY27 was Rs. 2,539.55 Lakhs.
What was the Basic Earnings Per Share (EPS) for Syncom Formulations in Q2 FY27?
Syncom Formulations' Basic Earnings Per Share (EPS) from continuing operations for Q2 FY27 was Rs. 0.27.
What were Syncom Formulations' total assets as of September 30, 2026?
Total Standalone Assets for Syncom Formulations as of September 30, 2026, were Rs. 56,588.27 Lakhs.
How did Syncom Formulations' current borrowings change as of Q2 FY27?
Current borrowings for Syncom Formulations increased to Rs. 1,552.36 Lakhs as of September 30, 2026, from Rs. 68.13 Lakhs as of March 31, 2026.
Questions based on this BSE filing only. For information purposes.